Skip to main content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Menu
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology

Liège Company Man & Science Reports Early Results From Cluster Headache Implant

November 19, 2026 Health Desk Health

A stimulator implant the size of a small button has been placed in ten patients with chronic cluster headache, and its Belgian developer, Man & Science, reported encouraging early results on Thursday.

Key Clinical Takeaways:

  • Man & Science, a medical technology company based in Liège, has implanted a mini neurostimulation device in ten patients in a pilot study.
  • The implant sits under the skin at the back of the head and stimulates the occipital nerve region without lead wires or a separate battery.
  • Attack frequency has fallen in the first patients, and no serious adverse events have been recorded so far, according to the company.
  • Final pilot results will determine whether clinical development continues toward regulatory approval and commercialization.

Ten implants, early signals

The device is being tested for safety and feasibility in patients whose cluster headache remains uncontrolled despite existing treatments, the company said. All ten implants have been placed as part of the pilot study.

“The first clinical results are encouraging,”

said Man & Science in its announcement, which hln.be reported on Thursday, November 19.

“The first results in the patients are encouraging,”

said professor Jean-Pierre Van Buyten, medical director and co-founder of Man & Science, who also heads the pain center at Vitaz hospital in Sint-Niklaas, according to HLN.

The early clinical signal the company points to is a reduction in attack frequency. Alongside it, Van Buyten and the company report that no serious adverse events have occurred with the implant so far. Both points remain preliminary: the study is small, uncontrolled at this stage, and designed to establish safety and feasibility rather than proof of efficacy.

What cluster headache does

Cluster headache brings recurring, intensely severe attacks, typically on one side of the head. An attack usually lasts between 15 minutes and three hours and can strike several times a day. When attacks recur without sustained remission, the condition is classed as chronic, and it carries substantial morbidity for patients whose attacks are not brought under control by the current standard of care.

It is precisely that treatment-resistant group that the pilot study targets. The pathogenesis of cluster headache is not fully mapped, which is why neuromodulation — intervening in pain signaling at the nerve level rather than through medication — has drawn interest for refractory cases.

Why the design drops the wires

The implant is placed under the skin at the back of the head to stimulate the occipital nerve region. According to the reporting by Gazet van Antwerpen, the mini-device requires no lead wires and no separately implanted battery — a structural difference from the systems in clinical use today.

That comparison matters. Occipital nerve stimulation is already performed off-label with spinal cord stimulation equipment, which runs under-skin lead wires to a pulse generator implanted elsewhere in the body. Man & Science’s device consolidates the architecture into a single unit at the stimulation site. Fewer components can mean a shorter procedure and fewer points of failure, though the pilot data will have to bear that out.

Man & Science funds implant; Van Buyten holds dual role

The implant was developed and is being funded by Man & Science itself, the Liège-based company behind the program; no external grant or partner funding is named in the company’s announcement. Van Buyten, as co-founder and medical director, is both the developer’s clinical lead and a treating physician in the field — a dual role patients and referring specialists should weigh when reading the company’s early results.

The decisive test comes later in the pilot study. Its final results must show whether Man & Science can continue clinical development with an eye toward future regulatory approval and eventual commercialization of the implant.

Before then, the findings would typically need to advance through larger, controlled trials of the kind regulators such as the European Medicines Agency require for implantable devices — double-blind or sham-controlled designs are standard for neuromodulation studies because stimulation has a strong placebo component. The company has not said when final pilot data will be published.

For patients with refractory chronic cluster headache, the practical takeaway is narrower than the headline: this is an investigational device in a ten-patient feasibility study, not an approved therapy. Refractory cases are usually managed through specialized headache or interventional pain centers, where a neurologist or pain specialist can assess whether any neuromodulation option — established or experimental — fits the individual case.

Beyond cluster headache

Man & Science also sees applications for the same technology in other conditions, the company said. These include cervicogenic headache and occipital neuralgia, both of which involve peripheral nerve stimulation — the same mechanism the occipital implant exploits. Expanding the indication would multiply the device’s market, but each new condition would need its own clinical evidence and its own regulatory review.

The open question is whether a reduction in attack frequency among ten patients, without serious adverse events so far, survives the scrutiny of final pilot results and larger controlled trials. Until those data exist, the company’s claim rests on its own words: “The first clinical results are encouraging.”


Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Worth a look

  • IBM France and Probabl Partner to Accelerate Industrialized Tabular AI and Governance
  • Almax Workers Announce Strike Over Unpaid Wages and Poor Working Conditions
  • Anthropic IPO Priced at Over $1 Trillion Valuation, Axios Reports (time.news)

Related

Search:

World Today News

World Today News is your trusted source for global journalism — breaking headlines, in-depth analysis, and reporting from around the world.

Quick Links

  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

Browse by Location

  • GB
  • NZ
  • US

Connect With Us

© 2026 World Today News. All rights reserved. Your trusted global news source directory.
For contact, advertising, copyright, issues email: [email protected]

Privacy Policy Terms of Service